Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
Martin WG Brinkhof, François Dabis, Landon Myer, David R Bangsberg, Andrew Boulle, Denis Nash, Mauro Schechter, Christian Laurent, Olivia Keiser, Margaret May, Eduardo Sprinz, Matthias Egger, Xavier Anglaret, for the ART-LINC of IeDEA collaboration
Volume 86, Number 7, July 2008, 559-567
Table 1. Characteristics of the ART programmes that contributed data to the analysis
| Region and programme name | Country | Number ofpatientsstarting ARTby 2004a | Number of patients eligible for analysis | Median CD4-cell count(cells/µl) | Freeaccess to treatment | Tracing method for patientslost tofollow-up | Status 6 months afterthe start of ART |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nofollow-up |
Initially followed up, then lost |
Knownto have died |
|||||||||||
| (n) | (%)b | (n) | (%)b | (n) | (%)b | ||||||||
| Morocco ART Cohort | Morocco | 423 (127; 270) | 412 | 108 | Yes | Phoneor letter | 0 | 0 | 47 | 11 | 15 | 3.6 | |
| Gaborone Independent | Botswana | 288 (228; 279) | 213 | 185 | No | Phoneor letter | 1 | 0.5 | 10 | 4.7 | 2 | 0.9 | |
| Lighthouse | Malawi | 1520 (0; 732) | 1219 | 56 | No | None | 109 | 8.9 | 441 | 36 | 36 | 3.0 | |
| CTAC | SouthAfrica | 313 (275; 307) | 305 | 241 | Yes | Home visits | 0 | 0 | 10 | 3.3 | 1 | 0.3 | |
| Khayelitsha | SouthAfrica | 287 (0; 287) | 273 | 45 | Yes | Home visits | 0 | 0 | 0 | 0 | 34 | 13 | |
| OPERA | SouthAfrica | 63 (1; 54) | 46 | 87 | Yes | Phoneor letter | 0 | 0 | 0 | 0 | 0 | 0 | |
| Eldoret | Kenya | 1138 (0; 223) | 839 | 94 | Yes | Home visits | 33 | 3.9 | 142 | 17 | 6 | 0.7 | |
| Cotrame ANRS 1203 | Côted’Ivoire | 137 (43; 128) | 123 | 133 | Yes | Home visits | 0 | 0 | 0 | 0 | 8 | 6.5 | |
| Nigeria HAART | Nigeria | 115 (2; 36) | 44 | 213 | No | Phoneor letter | 0 | 0 | 0 | 0 | 3 | 6.8 | |
| ISAARV | Senegal | 153 (140; 153) | 148 | 125 | Yes | Home visits | 0 | 0 | 6 | 4.1 | 6 | 4.1 | |
| HIMS | Various | 104 (0; 61) | 59 | 142 | Yes | Phoneor letter | 2 | 3.4 | 2 | 3.4 | 0 | 0 | |
| Rio de Janeiro HIV | Brazil | 789 (378; 654) | 541 | 166 | Yes | None | 0 | 0 | 28 | 5.2 | 2 | 0.4 | |
| SobrHIV | Brazil | 854 (640; 800) | 516 | 161 | Yes | None | 3 | 0.6 | 25 | 4.8 | 1 | 0.2 | |
| YRG CARE | India | 1367 (84; 744) | 717 | 83 | No | None | 63 | 8.8 | 169 | 24 | 27 | 3.8 | |
| HIV NAT | Thailand | 100 (76; 85) | 36 | 121 | Yes | Phoneor letter | 0 | 0 | 0 | 0 | 0 | 0 | |
| – | – | – | – | ||||||||||
ANRS, Agence Nationale de Recherches sur le Sida et les hépatites virales; ART, antiretroviral therapy; CTAC, Cape Town AIDS Cohort; HAART, highly active antiretroviral therapy; HIMS, Heineken International Medical Services; ISAARV, Senegalese Initiative on Access to Antiretroviral Drugs; NAT, Netherlands–Australia–Thailand Research Collaboration; OPERA, Operational Research on Antiretrovirals; SobrHIV, South Brazil HIV cohort; YRG CARE, YR Gaitonde Centre for AIDS Research and Education.a Values in parentheses are: number of patients starting ART < 2001; number of patients starting ART < 2003.b The percentages given are for the individual programmes.